Brief: Advicenne FY Net Loss Widens To 14.2 Million Euros

Advicenne SA

13/03/2020 08:38

March 13 (Reuters) - ADVICENNE SA  ADVIC.PA :
    * FY NET LOSS EUR 14.2 MILLION VERSUS LOSS OF EUR 5.0
MILLION YEAR
AGO
    * FY OPERATING LOSS EUR  14.2 MILLION VERSUS LOSS OF EUR 5.3
MILLION YEAR AGO
    * FY REVENUE EUR  1.6 MILLION VERSUS EUR 1.0 MILLION YEAR
AGO
    * 2020 WILL PRIMARILY BE DEVOTED TO PREPARING EUROPEAN
LAUNCH OF
ADV7103, WHOSE APPLICATION FOR MARKETING AUTHORIZATION IS UNDER
REVIEW WITH THE EMA’S COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN
USE (CHMP). A DECISION IS EXPECTED IN 2020
    * TOTAL REVENUE FROM CURRENT ACTIVITY EUR  2.58 MILLION
VERSUS EUR
6.92 MILLION YEAR AGO
    * OUTLOOK IN 2020 ADVICENNE WILL ALSO CONTINUE TO PURSUE ITS
INVESTMENT IN PHASE III CLINICAL TRIALS IN EUROPE, CANADA AND IN
THE UNITED STATES IN THE TREATMENT OF DRTA AND CYSTINURIA
    * OUTLOOK 2020-2021 THE COMPANY HAS ALSO SUBMITTED ITS FIRST
REQUESTS FOR ORPHAN DRUG DESIGNATION IN THE UNITED STATES
    * AT THE CLOSE OF 2019, ADVICENNE'S CASH AND CASH
EQUIVALENTS WERE
AT €16.6 MILLION, REFLECTING LIMITED CONSUMPTION OF €9.6 MILLION
FOR THE YEAR
    * FY CASH FLOW LOSS OF EUR 9.5 MILLION VERSUS LOSS OF EUR
10.2
MILLION YEAR AGO

Source text for Eikon:  ID:nBw7chmbja 
Further company coverage:  ADVIC.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))